Joanne Mortimer1, Helene B Zonder, Sumanta K Pal. 1. Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA. jmortimer@coh.org
Abstract
BACKGROUND: Bevacizumab is an important agent in the oncologic armamentarium, with activity in a broad spectrum of solid tumors. It has been approved in the management of metastatic colorectal cancer, non-small cell lung cancer, renal cancers, and recurrent glioblastoma multiforme. METHODS: We reviewed the published literature and briefing documents of the US Food and Drug Administration that provided the data leading to approval or change in approval status. RESULTS: Bevacizumab initially received accelerated approval for the treatment of advanced breast cancer. However, lack of confirmatory data from additional clinical trials resulted in the loss of that indication. Both the expected and unexpected toxicities reported from clinical trials using bevacizumab have helped us to understand the drug's mechanism of action and to identify who are most likely to benefit from this important agent. CONCLUSIONS: The side effects of treatment may provide important information about drug mechanism and efficacy. Bevacizumab is clearly an important agent in oncology and is likely to become more significant once a clinical or pathological marker to predict its efficacy has been identified.
BACKGROUND:Bevacizumab is an important agent in the oncologic armamentarium, with activity in a broad spectrum of solid tumors. It has been approved in the management of metastatic colorectal cancer, non-small cell lung cancer, renal cancers, and recurrent glioblastoma multiforme. METHODS: We reviewed the published literature and briefing documents of the US Food and Drug Administration that provided the data leading to approval or change in approval status. RESULTS:Bevacizumab initially received accelerated approval for the treatment of advanced breast cancer. However, lack of confirmatory data from additional clinical trials resulted in the loss of that indication. Both the expected and unexpected toxicities reported from clinical trials using bevacizumab have helped us to understand the drug's mechanism of action and to identify who are most likely to benefit from this important agent. CONCLUSIONS: The side effects of treatment may provide important information about drug mechanism and efficacy. Bevacizumab is clearly an important agent in oncology and is likely to become more significant once a clinical or pathological marker to predict its efficacy has been identified.
Authors: Toni K Choueiri; Erica L Mayer; Youjin Je; Jonathan E Rosenberg; Paul L Nguyen; Georges R Azzi; Joaquim Bellmunt; Harold J Burstein; Fabio A B Schutz Journal: J Clin Oncol Date: 2011-01-04 Impact factor: 44.544
Authors: Timothy J Perren; Ann Marie Swart; Jacobus Pfisterer; Jonathan A Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Mark S Carey; Philip Beale; Andrés Cervantes; Christian Kurzeder; Andreas du Bois; Jalid Sehouli; Rainer Kimmig; Anne Stähle; Fiona Collinson; Sharadah Essapen; Charlie Gourley; Alain Lortholary; Frédéric Selle; Mansoor R Mirza; Arto Leminen; Marie Plante; Dan Stark; Wendi Qian; Mahesh K B Parmar; Amit M Oza Journal: N Engl J Med Date: 2011-12-29 Impact factor: 91.245
Authors: Herbert I Hurwitz; Leonard B Saltz; Eric Van Cutsem; James Cassidy; Jonas Wiedemann; Florin Sirzén; Gary H Lyman; Ulrich-Peter Rohr Journal: J Clin Oncol Date: 2011-03-21 Impact factor: 44.544
Authors: Kathy D Miller; Linnea I Chap; Frankie A Holmes; Melody A Cobleigh; P Kelly Marcom; Louis Fehrenbacher; Maura Dickler; Beth A Overmoyer; James D Reimann; Amy P Sing; Virginia Langmuir; Hope S Rugo Journal: J Clin Oncol Date: 2005-02-01 Impact factor: 44.544
Authors: David W Miles; Arlene Chan; Luc Y Dirix; Javier Cortés; Xavier Pivot; Piotr Tomczak; Thierry Delozier; Joo Hyuk Sohn; Louise Provencher; Fabio Puglisi; Nadia Harbeck; Guenther G Steger; Andreas Schneeweiss; Andrew M Wardley; Andreas Chlistalla; Gilles Romieu Journal: J Clin Oncol Date: 2010-05-24 Impact factor: 44.544
Authors: Suresh S Ramalingam; Suzanne E Dahlberg; Corey J Langer; Robert Gray; Chandra P Belani; Julie R Brahmer; Alan B Sandler; Joan H Schiller; David H Johnson Journal: J Clin Oncol Date: 2008-01-01 Impact factor: 44.544
Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245
Authors: Christopher G Willett; Yves Boucher; Emmanuelle di Tomaso; Dan G Duda; Lance L Munn; Ricky T Tong; Daniel C Chung; Dushyant V Sahani; Sanjeeva P Kalva; Sergey V Kozin; Mari Mino; Kenneth S Cohen; David T Scadden; Alan C Hartford; Alan J Fischman; Jeffrey W Clark; David P Ryan; Andrew X Zhu; Lawrence S Blaszkowsky; Helen X Chen; Paul C Shellito; Gregory Y Lauwers; Rakesh K Jain Journal: Nat Med Date: 2004-01-25 Impact factor: 53.440
Authors: Zheqiong Yang; Min Peng; Liang Cheng; Kimya Jones; Nita J Maihle; Nahid F Mivechi; Lan Ko Journal: Am J Pathol Date: 2016-03-18 Impact factor: 4.307
Authors: Chun Huang; Xuan Wang; Jing Wang; Li Lin; Zhujun Liu; Wenjing Xu; Liuchun Wang; Jianyu Xiao; Kai Li Journal: Thorac Cancer Date: 2014-08-25 Impact factor: 3.500
Authors: N García-Romero; I Palacín-Aliana; R Madurga; J Carrión-Navarro; S Esteban-Rubio; B Jiménez; A Collazo; F Pérez-Rodríguez; A Ortiz de Mendivil; C Fernández-Carballal; S García-Duque; J Diamantopoulos-Fernández; C Belda-Iniesta; R Prat-Acín; P Sánchez-Gómez; E Calvo; A Ayuso-Sacido Journal: BMC Med Date: 2020-06-22 Impact factor: 8.775